Ratings by Leerink (Daniel Clark)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | ANI Pharmaceuticals | ANIP | New Coverage | Outperform (N/A) |
70.23 (72.29) |
2.93% | Details | |
| 9/9/2026 | Teva Pharma | TEVA | New Coverage | Outperform (N/A) |
36.76 (41.50) |
12.89% | Details | |
| 9/9/2026 | Collegium Pharmaceutical | COLL | New Coverage | Outperform (N/A) |
23.37 (23.19) |
-0.77% | Details | |
| 9/9/2026 | Bausch & Lomb Corp. | BLCO | New Coverage | Outperform (N/A) |
17.73 (16.49) |
-6.99% | Details | |
| 9/9/2026 | Amneal Pharmaceuticals | AMRX | New Coverage | Outperform (N/A) |
17.05 (19.18) |
12.49% | Details | |
| 9/9/2026 | Phathom Pharmaceuticals | PHAT | New Coverage | Market Perform (N/A) |
9.43 (6.92) |
-26.62% | Details | |
| 9/9/2026 | Nautilus Biotechnology | NAUT | New Coverage | Outperform (N/A) |
0.93 (2.06) |
121.51% | Details | |
| 9/9/2026 | Pacira Pharmaceuticals | PCRX | New Coverage | Market Perform (N/A) |
25.87 (36.34) |
40.47% | Details | |
| 9/9/2026 | Viatris | VTRS | New Coverage | Outperform (N/A) |
16.61 (18.66) |
12.34% | Details | |
| 9/9/2026 | Harrow Health | HROW | New Coverage | Outperform (N/A) |
37.85 (27.28) |
-27.93% | Details | |
| 3/10/2026 | Zoetis Inc. | ZTS | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/24/2026 | Elanco Animal Health | ELAN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2026 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Elanco Animal Health | ELAN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Elanco Animal Health | ELAN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Zoetis Inc. | ZTS | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/3/2025 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/17/2025 | Zoetis Inc. | ZTS | Downgrade | Market Perform (Outperform) |
151.54 (79.38) |
-47.62% | Details | |
| 7/17/2025 | Elanco Animal Health | ELAN | Upgrade | Outperform (Market Perform) |
14.51 (23.55) |
62.3% | Details | |
| 6/26/2025 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2025 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2025 | Elanco Animal Health | ELAN | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/7/2025 | Elanco Animal Health | ELAN | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/6/2025 | Zoetis Inc. | ZTS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2024 | IDEXX Laboratories | IDXX | New Coverage | Outperform (N/A) |
421.75 (560.36) |
32.87% | Details | |
| 12/2/2024 | Elanco Animal Health | ELAN | New Coverage | Market Perform (N/A) |
13.21 (23.55) |
78.27% | Details | |
| 12/2/2024 | Zoetis Inc. | ZTS | New Coverage | Outperform (N/A) |
175.25 (79.38) |
-54.7% | Details |
